Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.82 |
| ▸ | F2 | P00734 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177790 | 0.90 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL10063542 | 0.88 | F10 (0.88) | F10KCNH2F2 | |
| SCHEMBL12045550 | 0.88 | F10 (0.68) | F10KCNH2 | |
| SCHEMBL799840 | 0.87 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL10181142 | 0.87 | F10 (0.85) | F10KCNH2F2 | |
| SCHEMBL10146279 | 0.87 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL12132919 | 0.87 | F10 (0.85) | F10KCNH2F2 | |
| Betrixaban SCHEMBL158591 | 0.85 | F10 (1.00) | F10KCNH2F2 | |
| Betrixaban SCHEMBL29374026 | 0.85 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL12134308 | 0.85 | F10 (0.82) | F10KCNH2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028510-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | ALEXION PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9555023-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160101089-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-9221758-B2 | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150224091-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | PORTOLA PHARMACEUTICALS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-9061019-B2 | Pharmaceutical salts and polymorphs of a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-8987463-B2 | Methods of synthesizing factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8946219-B2 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946269-B2 | Crystalline forms of a factor Xa inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140323497-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140288028-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140046071-A1 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8455440-B2 | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130064806-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-20120095019-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | ALEXION PHARMACEUTICALS, INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120071519-A1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | ALEXION PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326119-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | F10 10/4885KCNH2 3549/4885F2 7/4885 |
| US-20150224091-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | SERPINC1, TBXA2R, PLAT | F10 37/4885KCNH2 2677/4885F2 12/4885 |
| US-20120071519-A1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | F12, F9, F11 | F10 5/4885KCNH2 2595/4885F2 8/4885 |
| US-20140046071-A1 | Methods of Synthesizing Pharmaceutical Salts of a Factor Xa Inhibitor | F12, F11, TFPI | F10 12/4885KCNH2 2097/4885F2 11/4885 |
| US-20130064806-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | F10 10/4885KCNH2 3549/4885F2 7/4885 |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | SERPINC1, F2, TFPI | F10 6/4885KCNH2 1976/4885F2 2/4885 |
| US-20140323497-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | ABCB1, PLAT, TFPI | F10 32/4885KCNH2 728/4885F2 31/4885 |
| US-20140288028-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | F10 10/4885KCNH2 3549/4885F2 7/4885 |
| US-20120095019-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | ABCB1, PLAT, TFPI | F10 32/4885KCNH2 728/4885F2 31/4885 |
| US-20130211094-A1 | METHODS OF SYNTHESIZING FACTOR Xa INHIBITORS | F12, F9, F7 | F10 11/4885KCNH2 1354/4885F2 10/4885 |
| US-20180028510-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | SERPINC1, TBXA2R, PLAT | F10 37/4885KCNH2 2677/4885F2 12/4885 |
| US-20160101089-A1 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR | F12, F11, TFPI | F10 10/4885KCNH2 3549/4885F2 7/4885 |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | F10 472/4885KCNH2 958/4885F2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.